SIGN UP

July 1, 2020 07:20 AM EDTUpdated July 2, 02:45 AM

Days after Intercept rejection, Akero surges on ‘unprecedented‘ NASH data

Jason Mast

Editor

A year and a half after scoring a $70 million Series B and a top Gilead executive as CEO, Akero Therapeutics has announced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

sponsored

Are programs with compounded GLP-1s safe for your population?